NATICK, Mass., June 04, 2007 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today welcomed the publication of an article in the Journal of of Cardiology (JACC) reviewing the TAXUS ATLAS clinical trial, which evaluates the Company's second-generation TAXUS(R) Liberte(TM)(1) paclitaxel-eluting stent system. The article in the April 24 edition of JACC concluded that the shorter procedure time and lower bailout rate of the TAXUS Liberte Stent system compared to the TAXUS(R) Express2(TM) Stent system may represent a clinical surrogate for the improved deliverability and conformability of the TAXUS Liberte Stent as compared to the TAXUS Express Stent.
TAXUS ATLAS is a global, multi-center single arm trial comparing the TAXUS Liberte paclitaxel-eluting stent system to a case-matched control group of patients from the TAXUS IV and TAXUS V de novo studies that received the TAXUS Express2 paclitaxel-eluting stent system. Even with more complex lesion characteristics(2) compared to the control group, the TAXUS ATLAS trial met its primary endpoint of nine-month target vessel revascularization (TVR) non-inferiority.
The TAXUS ATLAS nine-month results also support safety, as
demonstrated by low rates of Major Adverse Cardiac Events (MACE)
and stent thrombosis. The MACE rate and its components, including
cardiac death, myocardial infarction and TVR, were comparable to
control despite the higher percentage of complex lesions for the
TAXUS Liberte Stent arm. Cardiac death for the control group was
0.9 percent compared to 0.8 percent for the TAXUS Liberte Stent
(p=1.00). Myocardial infarction was 3.9 percent for the control
group compared to 3.7 percent for the TAXUS Liberte Stent
(p=0.9030). The nine-month TVR rate for the control group was 7.1
percent compared to 8.0 percent for the TAXUS Liberte Stent
(p=0.4787). Similar TVR rates of 9.2 percent for the TAXUS Liberte
Stent group, as compared to 8.9 perc